Number of risk factors versus infection after transrectal prostate biopsy: a nationwide population-based study
DOI:
https://doi.org/10.2340/sju.v61.45581Keywords:
Prostate biopsy, transrectal, complication, risk factor, infectionAbstract
Objective: It is unknown how risk factors for infection after transrectal prostate biopsy interact. We designed a study to evaluate this.
Methods: We identified biopsy procedures from 2006 to 2020 in the Swedish nationwide database PCBaSe. Primary outcome was post-biopsy infection, defined as a dispensed prescription of a urinary tract antibiotic and secondary outcome was inpatient care for infection both within 30 days. Risk factors were age, diabetes, medical treatment of lower urinary tract symptoms (LUTSs), prostate enlargement, immunosuppressives, corticosteroids, and defined antibiotic exposure during the past 1–12 months. When analysing risk in men with several risk factors clinically related factors were grouped as urinary tract infection (UTI)-antibiotics, treatment of LUTS, immunosuppressives including corticosteroids, and diabetes. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CI).
Results: A total of 139,056 transrectal prostate biopsy procedures were analysed. The grouped risk factors were significantly associated with post-biopsy infection (multivariable ORs: 1.22–1.72). Infection increased with number of risk factors; none: 4.0% (95% CI: 3.8–4.1), one: 6% (95% CI: 5.9–6.4), two: 10% (95% CI: 9.3–11), and three or four: 12% (95% CI: 9.8–14); inpatient care increased from 2.0% (95% CI: 1.9–2.1) to 3.1% (95% CI: 2.2–4.4).
Conclusion: Infection risk after transrectal prostate biopsy incrementally increases with the number of risk factors.
Clinical Implications: The transrectal biopsy route should be used with caution for patients with several risk factors for post-biopsy infections.
Patient Summary: Diabetes, urinary symptoms, previous urinary infection, and immune suppressing medication increase the risk of infection after a prostate biopsy through the rectum. Patients with many of these conditions have a particularly high risk.
What does the study add? We used nationwide register data to estimate the infection risk after transrectal prostate biopsy by the number of these risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year. The risk incrementally increased from 4.0% in men with no risk factor to 12% in those with 3 or 4.
Take Home Message: Infection after transrectal prostate biopsy increases with number of risk factors: diabetes, medical treatment of lower urinary tract symptoms, immunosuppressives including corticosteroids, and use of urinary tract antibiotics the past year, from 4.0% (none) to 12% (3 or 4).
Downloads
References
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876–892.
https://doi.org/10.1016/j.eururo.2013.05.049 DOI: https://doi.org/10.1016/j.eururo.2013.05.049
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–629.
https://doi.org/10.1016/j.eururo.2016.08.003 DOI: https://doi.org/10.1016/j.eururo.2016.08.003
Grummet J, Gorin MA, Popert R, et al. ‘TREXIT 2020’: why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis. 2020;23(1):62–65.
https://doi.org/10.1038/s41391-020-0204-8 DOI: https://doi.org/10.1038/s41391-020-0204-8
Mian BM. Prostate biopsy: hyperbole and misrepresentation versus scientific evidence and equipoise. Eur Urol. 2024;85(2):99–100.
https://doi.org/10.1016/j.eururo.2023.05.039 DOI: https://doi.org/10.1016/j.eururo.2023.05.039
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan. 2023 [cited 2024 Jul 18]. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/.
Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO Guideline Part II: considerations for a prostate biopsy. J Urol. 2023;210(1):54–63.
https://doi.org/10.1097/JU.0000000000003492 DOI: https://doi.org/10.1097/JU.0000000000003492
Hu JC, Assel M, Allaf ME, et al. Transperineal versus transrectal magnetic resonance imaging–targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol. 2024;86(1):61–68. DOI: https://doi.org/10.1016/j.eururo.2023.12.015
https://doi.org/10.1016/j.eururo.2024.04.014 DOI: https://doi.org/10.1016/j.eururo.2024.04.014
Mian BM, Feustel PJ, Aziz A, et al. Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial. J Urol. 2023;211(2):205–213.
https://doi.org/10.1097/JU.0000000000003788 DOI: https://doi.org/10.1097/JU.0000000000003788
Pradere B, Veeratterapillay R, Dimitropoulos K, et al. Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis. J Urol. 2021;205(3):653–663.
https://doi.org/10.1097/JU.0000000000001399 DOI: https://doi.org/10.1097/JU.0000000000001399
Lei H, Dong X, Li L, et al. Retrospective study of the etiology and risk factors of systemic inflammatory response syndrome after systematic transrectal ultrasound-guided prostate biopsy. Infect Drug Resist. 2020;13:3187–3193.
https://doi.org/10.2147/IDR.S256548 DOI: https://doi.org/10.2147/IDR.S256548
Lundstrom KJ, Drevin L, Carlsson S, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116–1122.
https://doi.org/10.1016/j.juro.2014.04.098 DOI: https://doi.org/10.1016/j.juro.2014.04.098
Roberts MJ, Bennett HY, Harris PN, et al. Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches. Urology. 2017;104:11–21.
https://doi.org/10.1016/j.urology.2016.12.011 DOI: https://doi.org/10.1016/j.urology.2016.12.011
Loeb S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61(6):1110–1114.
https://doi.org/10.1016/j.eururo.2011.12.058 DOI: https://doi.org/10.1016/j.eururo.2011.12.058
Örtegren J, Kohestani K, Elvstam O, et al. Risk factors for infection after transrectal prostate biopsy: a population-based register study. Eur Urol Open Sci. 2024;67:1–6.
https://doi.org/10.1016/j.euros.2024.06.015 DOI: https://doi.org/10.1016/j.euros.2024.06.015
Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: the National Prostate Cancer Register of Sweden and Prostate Cancer Data Base – a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.
https://doi.org/10.1093/ije/dyv305 DOI: https://doi.org/10.1093/ije/dyv305
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273.
https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284.
https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Stattin P. How to survey adherence to guidelines by use of clinical cancer registers. Scand J Urol. 2022;56(4):285–286.
https://doi.org/10.1080/21681805.2022.2107069 DOI: https://doi.org/10.1080/21681805.2022.2107069
Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol. 2009;43(5):342–349.
https://doi.org/10.3109/00365590903024577 DOI: https://doi.org/10.3109/00365590903024577
Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer Data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–967.
https://doi.org/10.1093/ije/dys068 DOI: https://doi.org/10.1093/ije/dys068
Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735.
https://doi.org/10.1002/pds.1294 DOI: https://doi.org/10.1002/pds.1294
Classification of Procedural codes The National Board of Health and Welfare; [cited 2024 Apr 02]. Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/klassifikationer-och-koder/kkakum2005-2020.pdf
Carlsson S, Bratt O, Stattin P, et al. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6): 405–410.
https://doi.org/10.3109/00365599.2012.691111 DOI: https://doi.org/10.3109/00365599.2012.691111
Styrke J, Resare S, Lundström K-J, et al. Current routines for antibiotic prophylaxis prior to transrectal prostate biopsy: a national survey to all urology clinics in Sweden. F1000Research. 2020;9:58.
https://doi.org/10.12688/f1000research.19260.1 DOI: https://doi.org/10.12688/f1000research.19260.1
Abughosh Z, Margolick J, Goldenberg SL, et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(4):1326–1331.
https://doi.org/10.1016/j.juro.2012.09.121 DOI: https://doi.org/10.1016/j.juro.2012.09.121
Cussans A, Somani BK, Basarab A, et al. The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review. BJU Int. 2016;117(5):725–731.
https://doi.org/10.1111/bju.13402 DOI: https://doi.org/10.1111/bju.13402
Holmbom M, Forsberg J, Fredrikson M, et al. Fluoroquinolone-resistant Escherichia coli among the rectal flora is the predominant risk factor for severe infection after transrectal ultrasound-guided prostate biopsy: a prospective observational study. Scand J Urol. 2023;58:32–37.
https://doi.org/10.2340/sju.v58.11920 DOI: https://doi.org/10.2340/sju.v58.11920
Chastain DB, Spradlin M, Ahmad H, et al. Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults. Clin Infect Dis. 2024;78(4):e37–e56.
https://doi.org/10.1093/cid/ciad474 DOI: https://doi.org/10.1093/cid/ciad474
Anastasiadis E, van der Meulen J, Emberton M. Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol. 2015;22(2):181–186.
https://doi.org/10.1111/iju.12634 DOI: https://doi.org/10.1111/iju.12634
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Joakim Örtegren, Olof Elvstam, Kimia Kohestani, Henrik Kjölhede, Johan Styrke, Pär Stattin, Anders Berglund, Ola Bratt
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
